NOT.F - Novartis AG

Frankfurt - Frankfurt Delayed Price. Currency in EUR
80.16
0.00 (0.00%)
As of 7:57PM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close80.16
Open0.00
Bid80.11 x 30000
Ask80.34 x 30000
Day's Range0.00 - 0.00
52 Week Range
Volume1,589
Avg. Volume0
Market Cap179.853B
Beta (3Y Monthly)0.24
PE Ratio (TTM)16.47
EPS (TTM)4.87
Earnings DateN/A
Forward Dividend & Yield2.51 (3.13%)
Ex-Dividend Date2019-03-04
1y Target EstN/A
  • MarketWatch

    Incyte reports positive results in late-stage trial of treatment for GVHD

    Incyte Corp. shares rose 1.2% in premarket trade Wednesday, after the biotech said a late-stage trial of a treatment for patients with steroid-refractory acute graft-versus-host disease, or GVHD, met its main goal of improving overall response rate. Wilmington, Delaware-based Incyte said there were no new safety signals in the phase 3 trial evaluating ruxolitinib (Jakafi). GVHD is a condition that can occur after the transfer of stem cells from a donor when the donated cells trigger an immune response and attack the recipient's organs. "GVHD is a challenging and serious disease, and physicians around the world need access to therapies that can improve outcomes for patients," said Peter Langmuir, M.D., group vice president, targeted therapies, at Incyte. The trial, which is sponsored by Novartis as well as Incyte, continues with results expected to be presented in 2020. Incyte shares have gained 23.5% in 2019, while the S&P 500 has gained 19.5%.

  • Sanofi opens new Framingham site amid $1.6B bet on bio-manufacturing
    American City Business Journals

    Sanofi opens new Framingham site amid $1.6B bet on bio-manufacturing

    Sanofi has invested $1.5 billion into expanding over the last five years as it competes with companies like new CEO Paul Hudson’s former company Novartis Corp.

  • Progenics Pharmaceuticals Needs a Treatment for Sickly Corporate Governance
    CorpGov.com

    Progenics Pharmaceuticals Needs a Treatment for Sickly Corporate Governance

    Progenics Pharmaceuticals, Inc. Pushed Through Questionable Merger with Votes from Directors Who Had Resigned Progenics Agreed to Large Termination Fee in Possible Move to Trap Shareholders in Deal Corporate Governance Expert Finds Termination Fee, Lame Duck Director Votes “Troubling” Stock Trading Above Offer Price, Suggesting Shareholders Want A Kiss or Deal Scrapped By John […]

  • New Novartis Drug Tabbed as Blockbuster
    GuruFocus.com

    New Novartis Drug Tabbed as Blockbuster

    Sales of treatment for macular degeneration predicted to top $1 billion by 2026 Continue reading...

  • Is Novartis AG  (NVS) A Good Stock To Buy According To Hedge Funds?
    Insider Monkey

    Is Novartis AG (NVS) A Good Stock To Buy According To Hedge Funds?

    How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

  • Here is Hedge Funds’ 30th Most Popular Stock Pick
    Insider Monkey

    Here is Hedge Funds’ 30th Most Popular Stock Pick

    Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]

  • Reuters

    CORRECTED-China expands drug bulk-buy programme, puts pressure on pharma firms

    China has expanded a pilot drug bulk-buying programme to the entire country in an attempt to negotiate lower prices from drug manufacturers, heaping fresh pressure on multinational pharmaceutical companies and their domestic rivals. The programme rolled out last year saw 11 Chinese cities, including Beijing and Shanghai, band together behind a tender process to bulk-buy 25 types of drugs. The scheme will be expanded to an additional 25 provinces and regions, who will form a league to look for suppliers for these drugs that will be stocked at public hospitals as well as some military and private medical institutions, according to documents released on Sunday by the drug procurement branch of the Shanghai Healthcare Security Administration.

  • The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation
    Benzinga

    The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Aug. 30.) Inspire Medical Systems Inc (NYSE: INSP ...

  • Novartis takes aim at Roche's star MS drug
    Reuters

    Novartis takes aim at Roche's star MS drug

    Swiss drugmaker Novartis on Friday stepped up its challenge to Roche's multiple sclerosis franchise, highlighting study results for its MS hopeful ofatumumab that could compete with its cross-town rival's drug Ocrevus. Novartis said ofatumumab, already approved as Arzerra to treat leukaemia, reduced annual relapses better than Sanofi's Aubagio in two head-to-head late-stage studies against relapsing forms of MS (RMS). Detailed study results are due at an MS conference in Sweden next month.

  • Reuters

    UPDATE 2-Novartis takes aim at Roche's star MS drug

    Swiss drugmaker Novartis on Friday stepped up its challenge to Roche's multiple sclerosis franchise, highlighting study results for its MS hopeful ofatumumab that could compete with its cross-town rival's drug Ocrevus. Novartis said ofatumumab, already approved as Arzerra to treat leukaemia, reduced annual relapses better than Sanofi's Aubagio in two head-to-head late-stage studies against relapsing forms of MS (RMS). Detailed study results are due at an MS conference in Sweden next month.

  • 5 Companies Still Run by Families
    Motley Fool

    5 Companies Still Run by Families

    In a world of large, faceless corporations, it can sometimes be nice to think of family values in business. What are the biggest family-owned businesses around?

  • 5 Biggest New Drug Approvals Potentially on the Way in 2019
    Motley Fool

    5 Biggest New Drug Approvals Potentially on the Way in 2019

    FDA approvals for these drugs could translate to billions of dollars for a few companies.

  • Novartis to answer U.S. Senate demand for data manipulation details
    Reuters

    Novartis to answer U.S. Senate demand for data manipulation details

    Novartis plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker's decision to delay informing regulators until after the treatment's approval. Novartis, which won approval for Zolgensma in May -- more than a month before it told the Food and Drug Administration of the alleged data fraud -- has terminated several scientists amid an internal investigation.

  • Novartis executive sold shares before drug data manipulation made public
    Reuters

    Novartis executive sold shares before drug data manipulation made public

    An unnamed Novartis executive sold 925,400 Swiss francs ($946,000) worth of shares less than three weeks before the U.S. Food and Drug Administration (FDA) announced data from tests of its gene therapy Zolgensma had been manipulated. Novartis announced the stock sale by an executive member of the board of directors or a member of the executive committee in a Swiss stock exchange filing dated July 19. The sale was made after the company had informed the FDA about the data manipulation but before the FDA announced it publically on Aug 6.

  • Motley Fool

    A Breach of Trust? Here's Why the FDA's Taking Aim at Novartis' AveXis

    What Novartis' misstep means to investors, plus how Exact Sciences is trying to lock up the genetic testing market.

  • Reuters

    Novartis replaces top scientists at Avexis after drug data manipulated

    Novartis AG said on Wednesday it replaced the two top research and development executives at its Avexis unit after some data was manipulated from early testing of a gene therapy for infants that costs more than $2 million. Avexis' Chief Scientific Officer Brian Kaspar and Senior Vice President of Research and Development Allan Kaspar have not been involved in any operations at Avexis since early May 2019, Novartis said in a statement. Brian Kaspar was a founder and key executive at Avexis and made more than $380 million from the company's 2018 acquisition by Novartis, according to SEC filings.

  • Novartis Reportedly Fires Brothers For Manipulating Gene Therapy Data
    Investor's Business Daily

    Novartis Reportedly Fires Brothers For Manipulating Gene Therapy Data

    Swiss pharma giant Novartis reportedly fired two scientists at its AveXis unit for manipulating data necessary to gain approval of gene therapy Zolgensma, CNBC reported Wednesday.

  • Reuters

    UPDATE 2-Novartis replaces top scientists at Avexis after drug data manipulated

    Novartis AG said on Wednesday it replaced the two top research and development executives at its Avexis unit after some data was manipulated from early testing of a gene therapy for infants that costs more than $2 million. Avexis' Chief Scientific Officer Brian Kaspar and Senior Vice President of Research and Development Allan Kaspar have not been involved in any operations at Avexis since early May 2019, Novartis said in a statement. Brian Kaspar was a founder and key executive at Avexis and made more than $380 million from the company's 2018 acquisition by Novartis, according to SEC filings.

  • Barrons.com

    Everyone’s Mad At Novartis. But the Stock Is Doing Just Fine

    Public pressure is heating up on Novartis A.G. over how the company handled a data manipulation issue, but the stock is doing just fine, thanks.

  • Novartis names Bulto as new head of U.S. drugs business
    Reuters

    Novartis names Bulto as new head of U.S. drugs business

    Swiss drugmaker Novartis has named company veteran Victor Bulto as head of its U.S. pharmaceuticals business, effective on Sept. 1. The statement said Chouraqui had "consistently demonstrated strong leadership, ethics and integrity" during his tenure. Bulto, who will report to Marie France Tschudin, global president of Novartis Pharmaceuticals, is a 14-year company veteran who has worked across every therapeutic area at the group and helped launch several products, including top-selling inflammation drug Cosentyx in the U.S. market.